At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Published:2020-03-27 Issue:1 Volume:191 Page:37-43
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ganzel Chezi¹²^ORCID,Wang Xin V.³,Rowe Jacob M.¹⁴,Richards Susan M.⁵,Buck Georgina⁵,Marks David I.⁶,Litzow Mark R.⁷,Paietta Elisabeth M.⁸,Foroni Letizia⁹,Luger Selina M.¹⁰,Willman Cheryl L.¹¹,Mullighan Charles G.¹²,Roberts Kathryn G.¹²,Wiernik Peter H.¹³,Douer Dan¹⁴,Lazarus Hillard M.¹⁵,Tallman Martin S.¹⁴,Goldstone Anthony H.¹⁶

Affiliation:

1. Shaare Zedek Medical Center JerusalemIsrael

2. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

3. Dana Farber Cancer Institute ‐ ECOG‐ACRIN Biostatistics Center Boston MA USA

4. Rambam Medical Center Haifa Israel

5. Clinical Trial Service Unit OxfordUK

6. University Hospitals Bristol National Health Service Foundation Trust Bristol UK

7. Mayo Clinic Rochester MNUSA

8. Montefiore Medical Center Bronx NY USA

9. Hammersmith Hospital London UK

10. University of Pennsylvania Philadelphia PAUSA

11. The University of New Mexico Albuquerque NMUSA

12. St Jude Children's Research Hospital Memphis TNUSA

13. Our Lady of Mercy Medical Center BronxNYUSA

14. Memorial Sloan Kettering Cancer Center New York NYUSA

15. Case Western Reserve University Cleveland OH USA

16. University College London London UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16616

Reference30 articles.

1. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

2. Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients

3. Outcome of pediatric acute lymphoblastic leukemia with very late relapse: a retrospective analysis by the Tokyo Children’s Cancer Study Group (TCCSG)

4. Late relapses after treatment for acute lymphoblastic leukemia in childhood: A population-based study from the nordic countries

5. Outcome of very late relapse in children with acute lymphoblastic leukemia;Rizzari C;Haematologica,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia;Frontiers in Pharmacology;2023-11-16

2. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC;Transplantation and Cellular Therapy;2023-06

3. Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy;Cytometry Part B: Clinical Cytometry;2023-03-30

4. Optimized outcome prediction of oncogenetic mutations in non-early T-cell precursor acute lymphoblastic leukemia;Immunobiology;2022-05

5. Outcome of adult acute lymphoblastic leukemia, a single-center experience;Iraqi Journal of Hematology;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3